How do I manage depression in an adult based on PHQ‑9 severity and suicidal risk?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 1, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Treat Depression Based on PHQ-9 Results

Manage depression in adults using a tiered approach based on PHQ-9 severity: scores 1-7 require supportive care and monitoring only; scores 8-14 mandate consultation with psychology or psychiatry for diagnostic confirmation; and scores ≥15 require immediate referral to mental health specialists for formal diagnosis and high-intensity treatment. 1

Immediate Safety Assessment (Overrides All Score-Based Management)

Before implementing any score-based algorithm, assess PHQ-9 item 9 regarding thoughts of self-harm. 1

  • Any endorsement of self-harm thoughts (regardless of total PHQ-9 score) requires immediate emergency psychiatric evaluation, one-to-one observation, and interventions to create a safe environment. 1
  • Never omit item 9 from assessment—doing so artificially lowers scores and misses critical suicide risk, even when total scores appear low. 1, 2
  • The frequency and specificity of self-harm thoughts determine acute risk level. 1

PHQ-9 Score Interpretation and Management Algorithm

Scores 1-7: None/Mild Symptomatology

No formal treatment is indicated; provide supportive care, patient education, and schedule reassessment. 1, 3

  • Patients typically demonstrate minimal depressive symptoms with effective coping skills and adequate social support. 1, 3
  • Provide education about: 1
    • Normalcy of stress responses
    • Spectrum of depressive symptoms
    • Available informational resources
  • Verify adequate coping mechanisms and social support systems are in place. 3
  • Schedule reassessment at 3,6, and 12 months, or during personal transitions, family crises, or changes in health status. 1, 3
  • Common pitfall: Do not initiate antidepressants or formal psychotherapy at this level—this represents overtreatment of mild symptoms that typically respond to supportive care. 3

Scores 8-14: Moderate Symptomatology

Refer to psychology or psychiatry for diagnostic confirmation and determination of appropriate intervention level. 1

  • This cutoff of ≥8 is based on diagnostic accuracy studies in clinical populations and supported by meta-analysis, demonstrating superior sensitivity compared to the traditional cutoff of 10. 1, 2
  • Patients exhibit most depressive symptoms with mild-to-moderate functional impairment. 1
  • After diagnostic confirmation, consider low-intensity interventions: 1
    • Psychosocial group interventions: Structured programs led by licensed mental health professionals addressing stress reduction, positive coping strategies (information-seeking, problem-solving, assertive communication), enhancing social support, and health behavior change. 1
    • Individual psychological therapy: Delivered by licensed professionals using treatment manuals incorporating cognitive change, behavioral activation, biobehavioral strategies, education, and relaxation techniques. 1
    • Pharmacologic treatment: Physician-prescribed antidepressants with choice informed by side-effect profiles, drug interactions, prior response, patient age, and preference; monitor regularly for adherence, side effects, and adverse events. 1

Scores 15-19: Moderate to Severe Symptomatology / Scores 20-27: Severe Symptomatology

Immediate referral to psychology and/or psychiatry for formal diagnosis and high-intensity treatment is mandatory. 1, 4

  • Patients present with the majority of depressive symptoms that interfere moderately to markedly with functioning. 1, 4
  • High-intensity interventions required: 1, 4
    • Individual psychological therapy using evidence-based treatment manuals that include cognitive behavioral therapy (CBT), behavioral activation, biobehavioral strategies, education, and relaxation strategies with relapse prevention components. 1, 4
    • Behavioral couples' therapy can be considered when a regular partner is present and relationship issues may contribute to depression development or maintenance. 1, 4
    • Pharmacologic treatment with close monitoring for efficacy, adherence, and adverse events. 1
  • Do not underestimate the severity of scores ≥15—this represents significant clinical depression requiring professional intervention, not primary care management alone. 4

Risk Factors That Warrant Immediate Referral (Even with Moderate Scores 8-14)

Presence of any of the following risk factors should prompt immediate psychiatry referral despite moderate PHQ-9 scores: 1, 3

  • Prior mood disorder (treated or untreated) 1, 3
  • Comorbid mood and/or anxiety disorders (e.g., generalized anxiety disorder) 1, 3
  • Current or past substance use disorder 1, 3
  • Recurrent, advanced, or progressive medical disease 1, 3
  • Social isolation (single, widowed, divorced) 1, 3
  • Unemployment with limited financial resources 1, 3
  • Low educational attainment (less than high school/GED) 1, 3
  • Presence of other chronic illnesses (e.g., coronary heart disease, chronic obstructive pulmonary disease) 1

Phased Screening Approach

Use a two-step screening process to maximize efficiency: 1, 2

  1. First, administer only the first two PHQ-9 items: 1
    • Little interest or pleasure in doing things (anhedonia)
    • Feeling down, depressed, or helpless (depressed mood)
  2. If either item scores 0-1, no further screening is needed. 1
  3. If either item scores 2-3 (more than half the days or nearly every day), complete the remaining seven PHQ-9 items. 1
  4. This approach reduces screening burden—only 25-30% of patients require completion of the full questionnaire. 1

Monitoring Treatment Response

Regularly reassess PHQ-9 scores to track treatment efficacy: 4, 5

  • A clinically meaningful change is defined as a 5-point reduction on the 0-27 scale. 5
  • Monitor at regular intervals during treatment and at 3,6, and 12 months after treatment completion. 1
  • The PHQ-9 demonstrates excellent responsiveness to treatment with effect sizes of -1.3 at both 3 and 6 months. 5

Special Populations and Considerations

Tailor assessment and treatment for specific populations: 1, 2

  • Use culturally sensitive assessments when possible. 1, 2
  • Modify assessment approaches for patients with learning disabilities or cognitive impairments—the PHQ-9 loses accuracy in cognitively impaired populations. 2
  • Detection of depression in older adults is particularly challenging and may require additional clinical judgment beyond PHQ-9 scores alone. 1, 2

Common Pitfalls to Avoid

  • Failing to assess item 9 (self-harm) in every patient, regardless of total score. 1, 3, 2
  • Initiating antidepressants or formal psychotherapy for scores 1-7, which represents overtreatment. 3
  • Managing scores ≥15 in primary care without specialist referral—these patients require high-intensity interventions from licensed mental health professionals. 1, 4
  • Not completing the full PHQ-9 when initial two-item screening suggests depression (scores 2-3 on either item). 2
  • Using the traditional cutoff of ≥10 instead of ≥8, which reduces sensitivity for detecting clinically significant depression. 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Significance of PHQ-9 Score for Depression

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Mild Depressive Symptoms

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment for Moderate to Severe Depression

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

How does the Patient Health Questionnaire-9 (PHQ-9) contribute to preventative care in patients with depressive symptoms?
As a provider, how should I manage a patient with a PHQ‑9 score of 19 (moderately severe depression)?
Is it appropriate to maintain the current plan—no medication change, safety monitoring, early psychotherapy referral, and 1–2 week follow‑up—for a 33‑year‑old female with severe depression (PHQ‑9 score 20) on escitalopram 20 mg daily who declines medication adjustment pending a sleep study and will select her own therapist?
Do you continue escitalopram (citalopram) 10mg 1/2 tab for a Patient Health Questionnaire-9 (PHQ-9) score of 6 indicating mild depression?
Can I increase Cymbalta (duloxetine) from 20mg daily to 40mg daily in a patient with moderate to severe depression and a Patient Health Questionnaire-9 (PHQ9) score of 14?
What are the possible causes of recurrent 15–20 lb (≈7–9 kg) weight fluctuations every 4–6 weeks in a patient with chronic gastro‑esophageal reflux disease, probable gastroparesis, iron‑deficiency anemia, vitamin D deficiency, and use of caffeine and lisdexamfetamine (Vyvanse), who does not vomit frequently?
How should I suspect and manage hepatic encephalopathy in an adult patient with known or suspected chronic liver disease (cirrhosis)?
Is a generic ipratropium bromide metered‑dose inhaler commercially available in the United States?
How should Group A Streptococcus (Streptococcus pyogenes) and Group B Streptococcus (Streptococcus agalactiae) isolated from a urine culture be interpreted and treated in pregnant versus non‑pregnant patients?
What key information should be given to a patient starting oseltamivir (Tamiflu) for influenza A infection?
How should a typical adult with lateral epicondylitis (tennis elbow) be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.